

Antonella Sistigu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3606179/publications.pdf>

Version: 2024-02-01

41
papers

8,864
citations

257450

24
h-index

302126

39
g-index

41
all docs

41
docs citations

41
times ranked

14728
citing authors

#	ARTICLE	IF	CITATIONS
1	Control of replication stress and mitosis in colorectal cancer stem cells through the interplay of PARP1, MRE11 and RAD51. <i>Cell Death and Differentiation</i> , 2021, 28, 2060-2082.	11.2	19
2	Microfluidic Co-Culture Models for Dissecting the Immune Response in in vitro Tumor Microenvironments. <i>Journal of Visualized Experiments</i> , 2021, , .	0.3	5
3	The Targeting of MRE11 or RAD51 Sensitizes Colorectal Cancer Stem Cells to CHK1 Inhibition. <i>Cancers</i> , 2021, 13, 1957.	3.7	8
4	Actin Cytoskeleton Dynamics and Type I IFN-Mediated Immune Response: A Dangerous Liaison in Cancer?. <i>Biology</i> , 2021, 10, 913.	2.8	2
5	The Yin and Yang of Type I IFNs in Cancer Promotion and Immune Activation. <i>Biology</i> , 2021, 10, 856.	2.8	21
6	The Immune Privilege of Cancer Stem Cells: A Key to Understanding Tumor Immune Escape and Therapy Failure. <i>Cells</i> , 2021, 10, 2361.	4.1	36
7	Assessment of IFN- β and granzyme-B production by in in vitro technology. <i>Methods in Enzymology</i> , 2020, 631, 391-414.	1.0	3
8	Cytofluorometric assessment of dendritic cell-mediated uptake of cancer cell apoptotic bodies. <i>Methods in Enzymology</i> , 2020, 632, 39-54.	1.0	1
9	Tuning Cancer Fate: Tumor Microenvironment's Role in Cancer Stem Cell Quiescence and Reawakening. <i>Frontiers in Immunology</i> , 2020, 11, 2166.	4.8	60
10	Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. , 2020, 8, e000337.		610
11	Tumor-Intrinsic or Drug-Induced Immunogenicity Dictates the Therapeutic Success of the PD1/PDL Axis Blockade. <i>Cells</i> , 2020, 9, 940.	4.1	8
12	Mutational and Antigenic Landscape in Tumor Progression and Cancer Immunotherapy. <i>Trends in Cell Biology</i> , 2019, 29, 396-416.	7.9	66
13	Disruption of IFN-I Signaling Promotes HER2/Neu Tumor Progression and Breast Cancer Stem Cells. <i>Cancer Immunology Research</i> , 2018, 6, 658-670.	3.4	34
14	Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. <i>Cell Death and Differentiation</i> , 2018, 25, 486-541.	11.2	4,036
15	CHK1-targeted therapy to deplete DNA replication-stressed, p53-deficient, hyperdiploid colorectal cancer stem cells. <i>Gut</i> , 2018, 67, 903-917.	12.1	64
16	Replication stress response in cancer stem cells as a target for chemotherapy. <i>Seminars in Cancer Biology</i> , 2018, 53, 31-41.	9.6	31
17	Type-I-interferons in infection and cancer: Unanticipated dynamics with therapeutic implications. <i>Oncolmmunology</i> , 2017, 6, e1314424.	4.6	106
18	IL-33 restricts tumor growth and inhibits pulmonary metastasis in melanoma-bearing mice through eosinophils. <i>Oncolmmunology</i> , 2017, 6, e1317420.	4.6	137

#	ARTICLE	IF	CITATIONS
19	The added value of type I interferons to cytotoxic treatments of cancer. <i>Cytokine and Growth Factor Reviews</i> , 2017, 36, 89-97.	7.2	25
20	Immunogenic stress and death of cancer cells: Contribution of antigenicity vs adjuvanticity to immunosurveillance. <i>Immunological Reviews</i> , 2017, 280, 165-174.	6.0	82
21	Mesenchymal traits at the convergence of tumor-intrinsic and -extrinsic mechanisms of resistance to immune checkpoint blockers. <i>Emerging Topics in Life Sciences</i> , 2017, 1, 471-486.	2.6	5
22	Molecular Mechanisms of Immunogenic Cell Death. , 2017, , .		0
23	Deciphering the loop of epithelial-mesenchymal transition, inflammatory cytokines and cancer immunoediting. <i>Cytokine and Growth Factor Reviews</i> , 2017, 36, 67-77.	7.2	71
24	LTX-315, CAPtivating immunity with necrosis. <i>Cell Cycle</i> , 2016, 15, 1176-1177.	2.6	3
25	Trial watch “inhibiting PARP enzymes for anticancer therapy. <i>Molecular and Cellular Oncology</i> , 2016, 3, e1053594.	0.7	19
26	Whole-genome duplication increases tumor cell sensitivity to MPS1 inhibition. <i>Oncotarget</i> , 2016, 7, 885-901.	1.8	31
27	Trial Watch: Targeting ATM“CHK2 and ATR“CHK1 pathways for anticancer therapy. <i>Molecular and Cellular Oncology</i> , 2015, 2, e1012976.	0.7	117
28	Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1. <i>Science</i> , 2015, 350, 972-978.	12.6	367
29	Autocrine signaling of type 1 interferons in successful anticancer chemotherapy. <i>Oncolmmunology</i> , 2015, 4, e988042.	4.6	27
30	Consensus guidelines for the detection of immunogenic cell death. <i>Oncolmmunology</i> , 2014, 3, e955691.	4.6	686
31	A multidisciplinary study using <i>in vivo</i> tumor models and microfluidic cell-on-chip approach to explore the cross-talk between cancer and immune cells. <i>Journal of Immunotoxicology</i> , 2014, 11, 337-346.	1.7	48
32	CCL2/CCR2-Dependent Recruitment of Functional Antigen-Presenting Cells into Tumors upon Chemotherapy. <i>Cancer Research</i> , 2014, 74, 436-445.	0.9	118
33	Cancer cell“autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. <i>Nature Medicine</i> , 2014, 20, 1301-1309.	30.7	823
34	IRF-8 Controls Melanoma Progression by Regulating the Cross Talk between Cancer and Immune Cells within the Tumor Microenvironment. <i>Neoplasia</i> , 2012, 14, 1223-IN43.	5.3	48
35	An Immunosurveillance Mechanism Controls Cancer Cell Ploidy. <i>Science</i> , 2012, 337, 1678-1684.	12.6	367
36	Cyclophosphamide Synergizes with Type I Interferons through Systemic Dendritic Cell Reactivation and Induction of Immunogenic Tumor Apoptosis. <i>Cancer Research</i> , 2011, 71, 768-778.	0.9	304

#	ARTICLE	IF	CITATIONS
37	Prerequisites for the Antitumor Vaccine-Like Effect of Chemotherapy and Radiotherapy. <i>Cancer Journal (Sudbury, Mass)</i> , 2011, 17, 351-358.	2.0	75
38	Immunomodulatory effects of cyclophosphamide and implementations for vaccine design. <i>Seminars in Immunopathology</i> , 2011, 33, 369-383.	6.1	265
39	Type I IFNs Control Antigen Retention and Survival of CD8 ⁺ Dendritic Cells after Uptake of Tumor Apoptotic Cells Leading to Cross-Priming. <i>Journal of Immunology</i> , 2011, 186, 5142-5150.	0.8	110
40	Human immunodeficiency virus type 1 (HIV-1) protease inhibitors block cell-to-cell HIV-1 endocytosis in dendritic cells. <i>Journal of General Virology</i> , 2009, 90, 2777-2787.	2.9	6
41	Macrophages Transmit Human Immunodeficiency Virus Type 1 Products to CD4-Negative Cells: Involvement of Matrix Metalloproteinase 9. <i>Journal of Virology</i> , 2007, 81, 9078-9087.	3.4	20